- Home
- ATOS vs NSPR Comparison
ATOS vs NSPR Comparison
Compare ATOS & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- NSPR
- Stock Information
- Founded
- ATOS 2009
- NSPR 2005
- Country
- ATOS United States
- NSPR United States
- Employees
- ATOS N/A
- NSPR N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- NSPR Medical/Dental Instruments
- Sector
- ATOS Health Care
- NSPR Health Care
- Exchange
- ATOS Nasdaq
- NSPR Nasdaq
- Market Cap
- ATOS 107.2M
- NSPR 101.8M
- IPO Year
- ATOS 2012
- NSPR N/A
- Fundamental
- Price
- ATOS $0.84
- NSPR $2.38
- Analyst Decision
- ATOS Strong Buy
- NSPR Strong Buy
- Analyst Count
- ATOS 3
- NSPR 2
- Target Price
- ATOS $6.17
- NSPR $4.50
- AVG Volume (30 Days)
- ATOS 473.0K
- NSPR 77.4K
- Earning Date
- ATOS 11-11-2025
- NSPR 11-11-2025
- Dividend Yield
- ATOS N/A
- NSPR N/A
- EPS Growth
- ATOS N/A
- NSPR N/A
- EPS
- ATOS N/A
- NSPR N/A
- Revenue
- ATOS N/A
- NSPR $7,066,000.00
- Revenue This Year
- ATOS N/A
- NSPR $7.48
- Revenue Next Year
- ATOS N/A
- NSPR $104.39
- P/E Ratio
- ATOS N/A
- NSPR N/A
- Revenue Growth
- ATOS N/A
- NSPR 7.60
- 52 Week Low
- ATOS $0.55
- NSPR $1.99
- 52 Week High
- ATOS $1.66
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- ATOS 60.84
- NSPR 44.77
- Support Level
- ATOS $0.81
- NSPR $2.35
- Resistance Level
- ATOS $0.80
- NSPR $2.46
- Average True Range (ATR)
- ATOS 0.03
- NSPR 0.08
- MACD
- ATOS 0.01
- NSPR -0.00
- Stochastic Oscillator
- ATOS 92.67
- NSPR 23.53
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.